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Stimulation of Activin A/Nodal signaling is insufficient to induce definitive
endoderm formation of cord blood-derived unrestricted somatic stem cells
Abstract
Introduction: Unrestricted somatic stem cells (USSC) derived from umbilical cord blood are an attractive
alternative to human embryonic stem cells (hESC) for cellular therapy. USSC are capable of forming cells
representative of all three germ line layers. The aim of this study was to determine the potential of USSC
to form definitive endoderm following induction with Activin A, a protein known to specify definitive
endoderm formation of hESC.
Methods: USSC were cultured for (1) three days with or without 100 ng/ml Activin A in either serum-free,
low-serum or serum-containing media, (2) three days with or without 100 ng/ml Activin A in combination
with 10 ng/ml FGF4 in pre-induction medium, or (3) four days with or without small molecules Induce
Definitive Endoderm (IDE1, 100 nM; IDE2, 200 nM) in serum-free media. Formation of definitive endoderm
was assessed using RT-PCR for gene markers of endoderm (Sox17, FOXA2 and TTF1) and lung
epithelium (surfactant protein C; SPC) and cystic fibrosis transmembrane conductance regulator; CFTR).
The differentiation capacity of Activin A treated USSC was also assessed.
Results
Results: Activin A or IDE1/2 induced formation of Sox17+ definitive endoderm from hESC but not from
USSC. Activin A treated USSC retained their capacity to form cells of the ectoderm (nerve), mesoderm
(bone) and endoderm (lung). Activin A in combination with FGF4 did not induce formation of Sox17+
definitive endoderm from USSC. USSC express both Activin A receptor subunits at the mRNA and protein
level, indicating that these cells are capable of binding Activin A.
Conclusions
Conclusions: Stimulation of the Nodal signaling pathway with Activin A or IDE1/2 is insufficient to induce
definitive endoderm formation from USSC, indicating that USSC differ in their stem cell potential from
hESC.
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Stimulation of Activin A/Nodal signaling is
insufficient to induce definitive endoderm
formation of cord blood-derived unrestricted
somatic stem cells
Caitlin E Filby1,2,3*, Robert Williamson1,2, Peter van Kooy4, Alice Pébay5, Mirella Dottori5, Ngaire J Elwood1,2 and
Faten Zaibak1,2

Abstract
Introduction: Unrestricted somatic stem cells (USSC) derived from umbilical cord blood are an attractive alternative
to human embryonic stem cells (hESC) for cellular therapy. USSC are capable of forming cells representative of all
three germ line layers. The aim of this study was to determine the potential of USSC to form definitive endoderm
following induction with Activin A, a protein known to specify definitive endoderm formation of hESC.
Methods: USSC were cultured for (1) three days with or without 100 ng/ml Activin A in either serum-free, low-serum
or serum-containing media, (2) three days with or without 100 ng/ml Activin A in combination with 10 ng/ml FGF4 in
pre-induction medium, or (3) four days with or without small molecules Induce Definitive Endoderm (IDE1, 100 nM;
IDE2, 200 nM) in serum-free media. Formation of definitive endoderm was assessed using RT-PCR for gene markers of
endoderm (Sox17, FOXA2 and TTF1) and lung epithelium (surfactant protein C; SPC) and cystic fibrosis transmembrane
conductance regulator; CFTR). The differentiation capacity of Activin A treated USSC was also assessed.
Results: Activin A or IDE1/2 induced formation of Sox17+ definitive endoderm from hESC but not from USSC.
Activin A treated USSC retained their capacity to form cells of the ectoderm (nerve), mesoderm (bone) and
endoderm (lung). Activin A in combination with FGF4 did not induce formation of Sox17+ definitive endoderm
from USSC. USSC express both Activin A receptor subunits at the mRNA and protein level, indicating that these
cells are capable of binding Activin A.
Conclusions: Stimulation of the Nodal signaling pathway with Activin A or IDE1/2 is insufficient to induce
definitive endoderm formation from USSC, indicating that USSC differ in their stem cell potential from hESC.

Introduction
Unrestricted somatic stem cells (USSC) are a population
of stem cells that can be isolated from umbilical cord
blood at birth. USSC have been shown to form the following cell types: nerve (ectoderm); heart, cartilage,
bone, fat and blood (mesoderm); and liver and lung
(endoderm) [1,2]. Although USSC have been shown to
form cells representative of all three germ line layers
[1,3,4], it is unclear whether USSC have an identical or
* Correspondence: filby@wehi.EDU.AU
1
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Full list of author information is available at the end of the article

a restricted capacity when compared to human embryonic stem cells (hESC).
Cord blood-derived USSC are an attractive source of
cells for therapy, as unlike hESC, they can be obtained
noninvasively at the time of birth, and have been shown
not to form teratomas in animal models [1,5]. Specific
factors or culture conditions cause USSC to be differentiated into progenitors of many cell types. Our research
group is investigating the potential of USSC to form
endodermal stem cells that may be useful for the treatment of cystic fibrosis and other diseases that affect the
lung, liver, pancreas, thyroid and gut.

© 2011 Filby et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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The developing endoderm gives rise to the lung, pancreas, liver, thyroid and gastrointestinal tract. Although
the precise mechanisms are yet to be elucidated, it is
apparent that the Nodal signaling pathway is involved in
normal endoderm specification during embryonic development [6,7] as well as in the in vitro differentiation of
stem cells into endoderm progenitors. Activin A is a
protein known to stimulate the Nodal signaling pathway.
Human ESCs [8-10] and induced pluripotent stem cells
(iPSC) [11], as well as mouse ESCs [12], respond to high
levels (100 ng/ml) of Activin A by commitment to
Sox17+ definitive endoderm (DE). On the other hand,
low levels of Activin A permits maintenance of pluripotency in stem cells [12,13]. In addition, stimulation of
the Nodal signaling pathway in hESC using small molecules such as the Induce Definitive Endoderm molecules
(IDE1 and IDE2) has also been shown to specify DE formation [14]. IDE1/2 induce phosphorylation of Smad2,
a key component of the Nodal signaling pathway [14].
In the current study, we tested whether high levels of
Activin A (alone or in combination with Fibroblast
Growth Factor 4; FGF4), or IDE1/2 in a low serum or
serum-free media causes USSC to form DE. We show
that unlike ESCs, USSC do not respond to Activin A or
IDE1/2 induction.

Materials and methods
Isolation and culture of USSC

Cord blood was collected with informed consent and
USSC lines were successfully generated and the phenotype of the lines characterized as described previously,
following a protocol approved by the University of Melbourne and the Royal Women’s Hospital Human Ethics
Review Committees (HREC No. 050886) [1,4,15]. The
USSC lines used in this study were negative for CD34,
CD24, CD31, CD45 and MHCII, and positive for CD44,
CD71 and MHCI. The multilineage capacity of the lines
was confirmed by differentiation into cells representative
of the three germ line layers.
Cryopreserved USSC were thawed rapidly at 37°C and
added to stem cell proliferation medium (SCPM), consisting of low-glucose Dulbecco’s modified Eagle Medium
(DMEM: Lonza, Walkersville, MD, USA) supplemented
with 30% fetal calf serum (FCS; Hyclone, Logan, UT,
USA), 0.1 mg/ml penicillin, 100 U/ml streptomycin (Invitrogen, Chadsworth, CA, USA) and 2 mM ultra glutamine
(Lonza). Cells were centrifuged (five minutes, 1,500 rpm),
the supernatant discarded and the cell pellet resuspended
in 10 ml of SCPM; this was repeated once. Resuspended
cells (approximately 106) were transferred to 75 cm2 flasks
and cultured at 37°C in 5% CO2. The medium was changed the day after thawing, and then every four to five days.
Cells were passaged once they reached 80% confluence;
medium was removed, cells were washed with phosphate-
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buffered saline (PBS), and then dissociated by incubation
with 4 ml of 0.25% v/v trypsin/0.02% v/v EDTA at 37°C
for 5 to 10 minutes. Trypsin was neutralised by the addition of 2 ml 4% human serum albumin (Albumex® 20,
CSL Limited, Parkville, VIC, Australia) in PBS. Cell numbers were determined using the Countess (Invitrogen),
by analysing 10 μl of a 50% cell suspension in trypan
blue. Dissociated cells were centrifuged (five minutes,
1,500 rpm), the supernatant discarded and the pellet
resuspended in SCPM to obtain 10 6 cells/10 ml which
were plated in 75 cm2 flasks (unless otherwise indicated).
USSC used in this study were seeded for testing at passage
five to passage nine.
Determination of USSC survival in low-serum media

To avoid problems due to variation in biologicals such
as fetal calf serum (FCS) or Matrigel, Activin A induction was performed in low serum or serum-free SCPM.
To determine if USSC survive these culture conditions,
three USSC cell lines were seeded in duplicate in SCPM
containing varying concentrations of FCS: 0% (serumfree SCPM), 1%, 2% and 30%. Cells (0.4 × 10 6 total,
4.1 × 104 cells/cm2) were seeded near confluency in sixwell plates in 2.5 ml of media/well. Cells were observed
and after seven days were dissociated, counted and cell
pellets snap frozen on dry ice for later determination of
Activin A receptor mRNA levels. Cell counts were calculated and expressed as a percentage of the number of
cells originally seeded.
Activin A induction of USSC

Lyophilized carrier-free recombinant human Activin A
(Catalogue No. 338-AC/CF, R&D Systems Inc., Minneapolis, MN, USA) was reconstituted in sterile PBS to a
stock concentration of 100 μg/ml. To ensure consistency
in induction, all vials of Activin A that were used were
from one of two batches. The same batch was used
across experiments that were directly compared to one
another. At least three USSC lines and two hESC lines
consisting of five colonies were tested for their response
to Activin A.
USSC at passage five were seeded into one of three different treatment groups: SCPM containing 30% FCS
(Normal serum control); SCPM containing 0 (Day 1),
0.2% (Day 2) and 2% (Day 3) FCS (Low serum control);
SCPM containing 100 ng/ml Activin A and 0% (Day 1),
0.2% (Day 2) and 2% (Day 3) FCS (Activin A) (Additional
File 1) as previously described [8].
Cells were initially seeded in the appropriate media
(either SCPM containing 30% or 0% FCS), depending on
the treatment group to which each was assigned. The
number of cells seeded depended on the treatment group,
as culturing USSC in serum-free SCPM results in a 50%
loss in cell number. Hence, cells were seeded in 145 cm2
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dishes containing 25 ml media at a density of 3.3 ×
104 cells/cm2 when cultured in serum-free SCPM or 2.0 ×
10 4 cells/cm 2 when cultured in standard SCPM. After
24 hr, the seeding media was replaced with the appropriate treatment media and cells were incubated for 72 hr.
Following the induction period, USSC were dissociated,
counted and a proportion of the cells (5 × 10 5 cells per
treatment) were centrifuged and the cell pellets frozen
for RNA extraction. The remaining cells from each treatment group were seeded in triplicate. Each culture was
divided into two, one of which was tested using each of
the three differentiation assays (described below) to allow
undifferentiated and differentiated samples of each triplicate to be compared. For RNA extraction, cells were
seeded at 5 × 105 cells in six-well plates. For immunohistochemistry, cells were seeded at 4.2 × 104 cells in chamberslides. For Alizarin Red staining, cells were seeded at
2 × 104 cells in 12-well plates.
Several other variations of this Activin A induction
strategy were attempted, including culturing the USSC
for the entire induction period in either serum-free
SCPM or SCPM containing 2% FCS supplemented with
100 ng/ml Activin A.
USSC differentiation assays

The following differentiation assays were performed on
Activin A treated USSC to determine whether Activin A
treatment affected USSC multipotency. To induce mesoderm differentiation, cells were cultured for 10 days in
proliferation medium containing DAG (10 -7 M dexamethasone, 50 μg/ml ascorbic acid and 10 mM glycerol-2phosphate disodium salt (all from Sigma-Aldrich Castle
Hill, NSW, Australia) as described by Jaiswal et al. [16]).
Differentiated cells were pelleted for RNA extraction and
PCR analysis (details below) or were stained with Alizarin
Red to detect calcium deposits from bone cells, indicating
successful mineralization. For Alizarin Red staining, cells
were fixed in 70% ice-cold ethanol (4°C, 10 minutes) and
stained with 1% Alizarin Red S (Sigma-Aldrich) in distilled
water, pH 4.2 (room temperature, 10 minutes). Cells were
washed in distilled water, layered with PBS (calcium and
magnesium free) and images were captured using a using
Leica DMIRB inverted microscope and AxioVision 4.2 software (Carl Zeiss AG, Oberkochen, Germany).
To demonstrate neuronal differentiation capacity, USSC
were cultured with a modified differentiation protocol for
12 days [15]. Briefly, cells were seeded in fibronectincoated wells (10 μg/ml poly-D-lysine, Sigma-Aldrich;
10 μg/ml fibronectin, Becton Dickinson, Franklin Lakes,
NJ, USA) and cultured in neural basal medium (NBM)
consisting of Neurobasal A with 2% B-27, 1% insulintransferrin-selenium-A, 1% N2, 2 mM L-glutamine,
100 U/ml penicillin and 0.1 mg/ml streptomycin (all
sourced from Invitrogen), supplemented with basic
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fibroblast growth factor epidermal growth factor (both
20 ng/ml, R&D Systems). Media were changed every two
days. At the end of the differentiation protocol, cells were
collected for PCR analysis. Successful differentiation was
determined by RT-PCR for expression of Nestin and Pax6.
To test for epithelial differentiation, cells were grown
in small airway growth medium (SAGM; Lonza) as
described by Berger et al. [17]. USSC were seeded at
5 × 105 cells per well in a six-well plate and then cultured in SAGM for eight days. Medium was changed
every two days. Successful differentiation was determined by RT-PCR for expression of surfactant protein
C (SPC).
Combined Activin A and FGF4 induction of USSC

USSC (USSC1 at passage 6, USSC2 at passage 9) were
seeded at 5 × 103 cells/cm2 in six-well plates in 3.5 ml
of SCPM and were cultured for 72 hr to reach 80%
confluency. For both USSC lines, the following treatments were performed in triplicate: SCPM containing
30% FCS (SCPM control); Pre-induction media (PIM;
DMEM low glucose:Hams F12 Salts containing Glutamax, Penicillin/streptomycin, 15 mM Hepes Buffer,
1 mM Sodium Pyruvate, 1 g/L BSA, 5 mM nicotinamide,1.5 μg/ml ethanolamine as described in Waclawczyk et al. [18]) containing 0% (Day 1), 0.5% (Days 2 to
3) FCS (PIM control); PIM containing 100 ng/ml Activin A and 0% FCS (Day 1), with the addition of 10 ng/
ml FGF4 (Catalogue No. 235-F4/CF, R&D Systems Inc.)
and 0.5% (Days 2 to 3) (Activin A + FGF4) as previously
described [18].
Following the induction period, USSC were dissociated, centrifuged and cell pellets frozen for RNA
extraction.
Controls for Activin A or FGF4 induction

To confirm Activin A activity, hESC (Envy or H9;
approved by the University of Melbourne Human
Research Ethics Committee, HREC No. 0605017.5) were
used as a positive control for Sox17 induction. hESC
(five colonies per replicate; two replicates) were cultured
in Roswell Park Memorial Institute medium (RPMI)
containing 100 ng/ml Activin A for 72 hr as described
previously [8].
To confirm FGF4 activity, NIH 3T3 fibroblasts were
used as a positive control; FGF4 has a mitogenic effect on
fibroblasts [19]. NIH 3T3 fibroblasts were seeded at 3 ×
103 cells/cm2 in six-well plates in DMEM high glucose
(Catalogue No. 12100046, Invitrogen) containing 10%
heat-inactivated serum and 3.4 g/L HCO3. After 24 hr, the
media was replaced with fresh media with/without FGF4
(0, 5, 10, 20 or 40 ng/ml; in triplicate). Following 48 hr of
FGF4 induction, cells were dissociated and enumerated to
determine the effect of FGF4 on total cell numbers.
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IDE1 or IDE2 induction of USSC and hESC

A small sample of IDE1 and IDE2 (10 nM in DMSO)
were kindly supplied by Professor Stuart Schreiber.
USSC were seeded at high density (10 5 cells/cm 2 ) in
SCPM in 48-well plates to ensure cell numbers high
enough to detect mRNA levels and to minimize media
volumes given the limiting amount of IDE1/2. Colonies
(one to two) of hESC (Envy, passage 94) were seeded
into wells of an eight-well chamberslide, on a feeder
layer of mouse embryonic fibroblasts, as previously
described [20]. Induction of USSC and hESC occurred
simultaneously with the same batch of IDE1/2. Two
replicates were assigned to each treatment group for
each cell type, except cells treated with IDE2, as insufficient sample permitted only one replicate per cell type.
USSC were treated for four days with (1) Normal USSC
media (SCPM), (2) Control media (RPMI) (3) RPMI
containing 100 nM IDE1, or (4) RPMI containing 200
nM IDE2. hESC were treated with (1) Normal hESC
media with serum, as previously described [20], (2) Control media (RPMI) (3) RPMI containing 100 nM IDE1,
or (4) RPMI containing 200 nM IDE2.
Cell morphology was observed and representative
photographs taken. After four days, USSC and hESC
were dissociated and the cell pellets frozen for RNA
extraction. Immunohistochemistry and differentiation
assays were not performed as the small sample of IDE1/
2 necessitated that only very small numbers of cells
could be treated.
RNA Extraction and PCR

Total RNA was extracted using the RNeasy Plus Mini Kit
(Activin A and low serum study; Qiagen, Germantown,
MD, USA) or RNeasy Plus Micro Kit (IDE study; Qiagen)
according the manufacturer’s protocol. RNA was quantified using a NanoDrop 1000 Spectrophotometer. cDNA
was synthesized from 250 ng RNA using random hexamers according to the manufacturer’s protocol (Superscript
III kit, Invitrogen). Real-time PCR reactions (25 μl) contained ABI 2 × SYBR Green PCR Master Mix (Applied
Biosystems, Mulgrave, VIC, Australia, containing SYBR
Green I Dye, AmpliTaq Gold DNA Polymerase, dNTPS
with dUTP, passive reference and optimized buffer components), 0.4 μM primers and cDNA template. Amplification conditions for real-time PCR reactions were: one
cycle at 95°C for 10 minutes; 40 cycles at 95°C for 30 sec,
60°C for 30 sec and 72°C for 1 minute; followed by melt
curve analysis (50 to 90°C, rising 1°C per 5 sec). Standard
and nested PCR reactions (25 μl) contained 10 × PCR buffer, 5 × Q solution, 200 nM dNTPs, 400 nM of each primer and 0.625 U Taq polymerase (Taq Core Kit, Qiagen,
Germantown, MD, USA). Amplification conditions for
standard and nested PCR reactions were: one cycle at
94°C for 2 to 3 minutes; 30 (nested) to 35 (standard) cycles
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at 94°C for 30 sec, 54 to 60°C for 30 sec and 72°C for
1 minute; followed by extension at 72°C for 2 to 10 minutes. Primer sequences and annealing temperatures are
detailed in Table 1. Positive controls were either spontaneously differentiated hESC or human bronchial epithelial
cells. Gene expression was analyzed for the following
genes: Sox17, FOXA2, TTF1, surfactant protein C (SPC),
cystic fibrosis transmembrane conductance regulator
(CFTR) (endoderm/lung markers), Nestin, Pax6 (ectoderm
markers), Mixl1 and Brachyury (mesoderm markers).
Efficiency correlations confirmed that the efficiency of
Sox17 was similar to that of GAPDH. The ΔΔCT
method was then used to determine the gene expression
levels, corrected for GAPDH.
ACVR Immunohistochemistry

USSC1 and USSC2 were seeded in duplicate in eightwell chamberslides (Permanox slides, Cat # 177445, Labtek, Brendale, QLD, Australia) in SCPM containing 30%
FCS (2.0 × 10 4 cells/cm 2 ) or in SCPM containing 0%
FCS (3.3 × 104 cells/cm2). Cells were fixed by removing
the media, performing two times five-minute washes in
PBS, then incubating the cells in 4% paraformaldehyde/
PBS at 4°C for five minutes. The paraformaldehyde was
removed and cells washed in PBS and stored at 4°C in
PBS+ until commencing immunohistochemistry.
Cells were permeabilised in 0.1% Triton-x in tris-buffered saline (TBS) for 10 minutes, washed in dH 2 O
before endogenous peroxidases were quenched in 3%
H 2 O 2 for 5 minutes. Cells were washed in dH2 O and
TBS before the cells were blocked with 0.5% BSA/TBS
for 30 minutes. Cells were then incubated with primary
antibody (all goat polyclonal IgG; 1:50; ACVR1b Cat. #
sc-5665; ACVR2a Cat. # sc-5667; ACVR2b Cat. # sc11984, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
or rabbit IgG (Cat. # sc-2027; 1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 0.5% BSA/TBS at
4°C overnight.
Cells were washed in TBS before incubation with the
secondary antibody (DAKO polyclonal rabbit anti-goat Ig
Biotinylated Cat. # E0466) for 1 hr. Cells were washed in
TBS before being incubated with Avidin-Biotinylated
enzyme Complex (Vectastain, Vector Laboratories,
Burlingame, CA, USA) for 30 minutes. Cells were washed
in TBS and 3,3’-diaminobenzidine (DAB) containing
10 μl/ml 6% H2O2 was added to the sections to induce
formation of a specific signal. Cells were washed in
dH2O, stained with Harris’ Haematoxylin and mounted
(Invitrogen Prolong Gold Aqueous mountant). TCam2
seminoma cells were used as a positive control.
Statistical analyses

The following differences were determined by a two-way
unpaired t-test (assuming equal variances): 1) differences
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Table 1 Primers used for PCR in this study
Gene

Primer sequences 5’-3’

PCR type

Annealing temp. (°C) Cycle number Amplicon size (bp)

ACVR1a

ACVR1a-F

TAA GCG TCA CAC TGC CAA AG

Real-time

60

40

89

ACVR1a-R

GTC ACT GGG GTA CTC GGA GA
Real-time

60

40

121

Real-time

60

40

137

ACVR1b
ACVR1c

ACVR1b-F

TGC AAC AGG ATC GAC TTG AG

ACVR1b-R

TGA GGA CAG GAG GAA CAC C

ACVR1c-F

TGG TCT GGC ACA CCT TCA TA

ACVR1c-R

TCA CAG CCA ACC CTA AGT CC

ACVR2a

ACVR2a-F

GCG TTT GCC GTC TTT CTT AT

Real-time

60

40

138

ACVR2b

ACVR2a-R
ACVR2b-F

TGT CAC CAT AAC ACG GTT CAA
CTC CTC TGG GGA TCG CTG T

Real-time

60

40

137

ACVR2b-R

CTT GTC CTG CTC GCC TTC
Standard

55

38

608

Standard

35

30

1051

Brachyury
CFTR

Brachyury-F

GAA CCA GCA CCC TGT GTC CAC

Brachyury-R

GCC ACG ACA AAA AGT CAC TGC

CFTR-F

ACT TTA AAG CTG TCA AGC CGT G

CFTR-R

CAT CAT AGG AAA CAC CAA A

CFTR (nested) CFTR-NF
FOXA2
GAPDH

MixL1
Nestin
SPC
SPC (nested)
Sox17
TTF1

AGC TGT CAA GCC GTG TTC TAG ATA

Nested

45

30

140

CFTR-NR
FOXA2-F

ATG AGG AGT GCC ACT TGC AAA
GGG AGC GGT GAA GAT GGA

Standard

55

35

89

FOXA2-R

TCA TGT TGC TCA CGG AGG AGT A

GAPDH-F

ATG GAG AAG GCT GGG GCT C

Real-time
and
standard

60

40

196

Standard

55

35

58

Standard

55

35

209

Standard

57

30

456

GAPDH-R

AAG TTG TCA TGG ATG ACC TTG

MixL1-F

CCG AGT CCA GGA TCC AGG TA

MixL1-R

CTC TGA CGC CGA GAC TTG G

Nestin-F

CAG CTG GCG CAC CTC AAG ATG

Nestin-R

AGG GAA GTT GGG CTC AGG ACT GG

SPC-F

AGC CAG AAA CAC ACG GAG AT

SPC-R

AGT GGA GCC GAT GGA GAA G

SPC-NF
SPC-NR

AAC GCC TTC TTA TCG TGG TG
GTG AGA GCC TCA AGA CTG G

Nested

57

30

313

Real-time

60

40

61

Standard

50

38

116

Sox17-F

GGC GCA GCA GAA TCC AGA

Sox17-R

CCA CGA CTT GCC CAG CAT

TTF1-F

ACC AGG ACA CCA TGA GGA AC

TTF1-R

GCT CAT GTT CAT GCC GCT

in cell proliferation indices between USSC cultured in
0%, 1%, 2% or 30% FCS and, 2) differences in Sox17 or
Brachyury mRNA levels between untreated, Activin A
treated and spontaneously differentiated hESC and normal
serum, low serum and Activin A treated USSC. Results
were considered statistically significant at P < 0.05.

Results
Determination of USSC survival in serum-free culture
media

Prior to inducing USSC with Activin A, the survival
potential of USSC in a low serum or serum-free environment was assessed. USSC seeded at confluence (4.2 ×
104 cells/cm2) and grown in SCPM containing 0%, 1%
and 2% retained 51.2%, 63.0% and 87.8% of the initial
seeding density of cells after seven days while cells

grown in 30% FCS increased (149.5%) (Additional
File 2), indicating that USSC can survive in low serum
or serum-free environments for a short period of time.
When seeded at 1.3 × 10 4 cells/cm 2 the number of
viable USSC is normally approximately 300% of initial
seeding density after five days of growth in SCPM containing 30% FCS. In the current experiment, USSC were
seeded in media containing 30% FCS at confluence;
therefore, only a slight increase in the initial seeding
density was obtained.
Activin A treatment of USSC does not induce DE formation

The three USSC lines tested did not express mRNA for
the DE marker Sox17 either before or after treatment
with 100 ng/ml Activin A using a step-wise increase in
FCS over three days (Figure 1), indicating that Activin A

Filby et al. Stem Cell Research & Therapy 2011, 2:16
http://stemcellres.com/content/2/2/16

Page 6 of 14

Figure 1 Sox17 mRNA levels following Activin A induction. Sox17 mRNA levels for untreated and Activin A treated USSC lines and
untreated, spontaneously differentiated and Activin A treated hESC. Sox17 mRNA levels were very low in untreated and Activin A treated USSC
lines (0.001-fold of untreated hESC). Sox17 mRNA levels were low in untreated hESC, moderately low in spontaneously differentiated hESC and
significantly up-regulated in Activin A treated hESC.

treatment of USSC does not induce the production of
Sox17+ DE. On the other hand, Sox17 mRNA levels are
very low in undifferentiated Envy hESC, increase 4-fold
in spontaneously differentiated Envy hESC and are upregulated 16-fold in Envy hESC treated with the same
Activin A induction strategy. Activin A treatment of
USSC using media containing either 0% or 2% FCS was
also assessed; however, neither of these strategies
resulted in up-regulation of Sox17 expression (data not
shown).
USSC retain the capacity for multipotency following
Activin A induction

The mRNA levels of markers of endoderm, ectoderm and
mesoderm were not different between untreated and
Activin A-treated USSC either before or following directed differentiation (Figure 2), indicating that USSC retain
their capacity for multipotency following Activin A
induction. Specifically, mRNA for Sox17, FOXA2, TTF-1
and CFTR were not detected in untreated or Activin A
treated USSC either prior to or following endodermal differentiation with SAGM. The level of SPC mRNA was
similar in both untreated and Activin A treated USSC
following endodermal differentiation with SAGM. mRNA
for Nestin was detected in both untreated and Activin A
treated USSC, and was upregulated after ectodermal differentiation. On the other hand, Pax6 mRNA was not

detected in USSC regardless of Activin A treatment or
ectodermal differentiation. Similarly, MixL1 mRNA was
detected in USSC regardless of Activin A treatment or
mesodermal differentiation, while Brachyury was only
detected in some of the USSC lines studied and only following mesodermal differentiation. USSC retained the
capacity to form cells capable of mineralization, as determined by the detection of calcium deposits using Alizarin
red staining (Figure 3).
Combined treatment of USSC with Activin A and FGF4
does not induce DE formation

The two USSC lines tested did not express Sox17 before
or after treatment with 100 ng/ml Activin A and 10 ng/
ml FGF4 indicating that Activin A in combination with
FGF4 does not induce the production of Sox17+ DE
from USSC (Figure 4). Activin A was shown to induce
Sox17 expression in H9 hESC, indicating that the Activin
A was active. Similarly, FGF4 was shown to have a mitogenic effect on NIH 3T3 cells, resulting in a dose-dependent increase in cell numbers following 48 hr of FGF4
treatment (Figure 5), indicating that the FGF4 was active.
IDE1/2 treatment of USSC does not induce DE formation

Following induction with IDE1/2, a proportion of USSC
developed a more rounded morphology (Figure 6). Neither
Sox17 nor Brachyury could be detected in untreated or
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Figure 2 Markers of endoderm, ectoderm and mesoderm differentiation in Activin A treated USSC following directed differentiation.
Representative gels depicting mRNA levels of the housekeeping gene GAPDH, endoderm markers Sox17, FOXA2, TTF-1, SPC and CFTR, ectoderm
markers Nestin and Pax6 and mesoderm markers MixL1 and Brachyury. mRNA levels were determined in Activin-A treated USSC, low serum
control USSC and serum-free controls before (Figure 2a) and following (Figure 2b) differentiation into cells representative of each of the three
germline layers. Spontaneously differentiated hESC and human bronchial epithelial cells were used as positive controls and undifferentiated
USSC were used as negative controls. + depicts RT positive cDNA, - depicts RT negative controls.

IDE1- or IDE2-treated USSC (Figure 7), indicating that
IDE1/2 do not induce DE or mesendoderm formation of
USSC. On the other hand, the level of Sox17 mRNA in
Envy hESC is moderate in undifferentiated Envy hESC,
elevated in spontaneously differentiated Envy hESC, and
significantly increased following treatment with IDE1 or
IDE2. Brachyury was also moderately expressed in Envy

hESC and highly expressed in spontaneously differentiated
Envy hESC. IDE2 but not IDE1 up-regulated the level of
Brachyury mRNA in Envy hESC.
USSC express Activin A receptors (ACVR)

USSC express mRNA for ACVR1a, ACVR1b, ACVR1c,
ACVR2a and ACVR2b when cultured in SCPM containing
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Figure 3 Alizarin red staining of USSC. Representative light micrographs depicting calcium deposits detected by Alizarin red staining in
Normal serum control, Low serum control and Activin A treated USSC (100×) before and after mesoderm differentiation.
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Figure 4 Sox17 mRNA levels following combined Activin A and FGF4 induction. Sox17 mRNA levels for untreated and Activin A and
Fibroblast Factor 4 treated USSC lines and untreated, spontaneously differentiated and Activin A treated hESC. Sox17 mRNA levels were very low
in untreated USSC cultured in SCPM or PIM and in USSC lines treated with Activin A and Fibroblast Factor 4. Sox17 mRNA levels were low in
untreated hESC, and significantly up-regulated in Activin A treated hESC and in spontaneously differentiated hESC.
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30% FCS as determined by RT-PCR. When cultured in
SCPM containing 0% FCS, the mRNA levels for ACVR1a,
ACVR1b, ACVR1c, ACVR2a and ACVR2b increases
approximately four-fold (Figure 8; P < 0.05). Immunohistochemistry analysis revealed that USSC also express
ACVR1b, ACVR2a and ACV2b protein when cultured in
SCPM containing 30% FCS (Figure 9). USSC continue to
express ACVR1b, ACVR2a and ACVR2b protein when
cultured in serum free conditions (SCPM containing 0%
FCS; Additional File 3).

0
0 ng/ml FGF4

5 ng/ml FGF4

10 ng/ml FGF4

20 ng/ml FGF4

40 ng/ml FGF4

FGF4 concentration

Figure 5 Fibroblast Growth Factor 4 is active. Fold change in
NIH 3T3 cell numbers following treatment with Fibroblast Growth
Factor 4. A dose-dependent increase in NIH 3T3 cell numbers was
observed with an increase in Fibroblast Growth Factor 4
concentration, indicating that the growth factor is active.
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G

Figure 6 Representative micrographs of IDE1/2-treated USSC.
USSC grown in SCPM (A, B), RPMI (C, D), or RPMI containing 100
nM IDE1 (E, F) or 200 nM IDE2 (G) (100×). A proportion of USSC
treated with IDE1/2 developed a rounded morphology (E, F, G).

Discussion
The results of this study demonstrate that Activin
A/Nodal signaling alone is insufficient to induce formation of Sox17+ endoderm from USSC. Activin A induction (100 ng/ml, 72 hrs) was tested in three independent
experiments in triplicate, using media that was serumfree, contained low serum (2%) or which had an incremental increase in serum (0, 0.2 and 2%). Activin A
treated USSC showed no change in their capacity to
form nerve-like (ectoderm), bone-like (mesoderm) or
lung-like (endoderm) cells, indicating that Activin A
treatment alone does not direct differentiation of USSC.
Small molecule induction of the Nodal signaling pathway using IDE1/2, which are highly efficient in inducing
DE formation of hESC [14], also does not result in DE
formation of USSC. Furthermore, we report that induction with Activin A in combination with FGF4 does not
induce Sox17+ DE formation of USSC. Finally, we show
that USSC express the ACVR and are therefore capable
of responding to Activin A signals.
Unlike USSC, Activin A induction of hESC line Envy
with an incremental increase in serum was sufficient to
cause a 16-fold increase in Sox17 mRNA levels, a level
of up-regulation that is similar to previous reports of
Activin A-induced hESC endoderm formation [8]. Similarly, the H9 hESC line also showed increased Sox17
mRNA levels in response to Activin A induction. H9
showed a similar trend to Envy, although the magnitude
was somewhat smaller. Hence, although there are differences between hESC lines, well characterized hESC lines
such as Envy and H9 respond to growth factor stimulation in a relatively robust, repeatable manner with a
similar trend in terms of expression of key markers of
differentiation. Similarly, IDE1/2 induction resulted in
up-regulation of Sox17 in hESC, confirming earlier
reports that IDE1/2 induce formation of DE from hESC
[14]. Although Brachyury mRNA was detected in
untreated hESC, there was no discernible increase in
Brachyury expression following IDE1/2 induction. This
may indicate that if hESC pass through a mesendoderm
intermediate that they may have already done so after
four days of IDE1/2 induction.
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Figure 7 {Sox17 and Brachyury levels following IDE1/2 induction. Sox17 (black bars) and Brachyury (white bars) mRNA levels for untreated and
IDE1/2 treated USSC lines and untreated, spontaneously differentiated and IDE1/2 treated hESC. Sox17 and Brachyury mRNA levels were very low in
untreated and IDE1/2 treated USSC lines. Sox17 and Brachyury mRNA levels were low in untreated hESC. Sox17 mRNA was significantly upregulated in IDE1/2 treated hESC. Brachyury expression was significantly up-regulated in IDE2 treated hESC and spontaneously differentiated hESC.
Data represent the mean ± SD of three PCR replicates from two cell culture replicates for each experimental treatment (*P < 0.05).

Unlike hESC, USSC appear to be a heterogeneous
population [21] (and our own observations), one that
still requires further characterization. Indeed, here we
report that USSC1 and USSC2 do not form Sox17+
cells when treated with Activin A in combination with
FGF4. We report that the growth factors Activin A and
FGF4 used in this study are active (as indicated by their
effect on hESC and NIH 3T3 cells respectively) but do
not induce Sox17 expression in USSC1 (derived in our
laboratory) and USSC2 (derived in Gesine Kogler’s
laboratory). Our results disagree with those of Waclawczyk and Kogler et al. [18] who found that the same
induction strategy induced formation of hepatocytes;
those USSC expressed Sox17 mRNA at Day 3 of directed differentiation and cytoplasmic Sox17 protein at Day
5. The significance of the cytoplasmic localization of the
transcription factor Sox17 in that study is unclear; it
may indicate that although Sox17 was present it was not
active. The results of the current study indicate that the
combination of Activin A and FGF4 is not a robust
induction protocol for inducing Sox17 expression in
USSC.
There are a number of possibilities why USSC do not
respond to Activin A signaling alone. Indeed, other

authors have shown that Activin A-induced DE formation in hESC (1) can be enhanced by the addition of
Wnt3a [10], sodium butyrate [22] or insulin transferrinselenium (ITS) [9], or (2) can be achieved only by ensuring phosphoinositide 3-kinases (PI3K) are suppressed
[23]. This study did not test these modified Activin A
induction strategies, so none of these possibilities can be
excluded. However, numerous studies (including the
current study) show that Activin A alone is sufficient
for endoderm formation from ESCs [8,12,24,25]. This
study can only conclude that unlike in hESC, in USSC
Activin A/Nodal signaling alone is insufficient to induce
DE formation.
We show that USSC express the necessary receptors
to respond to Activin A signaling. All USSC lines
expressed all five ACVRs at the mRNA level and express
ACVR1b, ACVR2a and ACVR2b at the protein level; the
combination of these receptors is sufficient for functional Activin A signaling [26]. USSC may lack other
functional components of the signaling cascade; further
studies that may elucidate this issue include those that
determine 1) receptor functionality using an Activin A
fluorokine assay, 2) nuclear localization of Smad2 or 3)
the baseline of Activin A signaling by addition of
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Figure 8 Activin receptor (ACVR) mRNA levels. ACVR mRNA levels for USSC cultured in SCPM containing 0% FCS, expressed as fold change
from mRNA levels in USSC cultured in control (SCPM containing 30% FCS). All ACVR mRNA levels are significantly increased in USSC cultured in
0% FCS, compared to USSC cultured in SCPM containing 30% FCS (*P < 0.05). Data represent the mean ± SD of three PCR replicates from four
cell lines for each experimental treatment.

Activin A inhibitors such as Follistatin or Inhibin in
USSC. Alternatively, interrogation of this signaling pathway may in fact reveal that USSC have all the required
Activin A signaling components, but may have passed
the developmental window in which they will respond
to Activin A by forming DE.
Although Activin A induction in combination with
other growth factors may be sufficient for specifying
committed cell types such as hepatocytes [18], growth
factors alone are unlikely to be sufficient for USSCSox17+ DE formation. We speculate that this may

reflect that USSC, although capable of forming cells
representative of all three germline layers, have a
restricted differentiation potential compared to hESC.
Indeed, USSC do not express Oct4 [4] but do express
Klf4 and c-Myc [27], while hESC express all of the pluripotency markers. Furthermore Kluth et al. [21] propose that USSC may be derived from the fetal liver,
hence USSC may have a greater propensity to form
hepatocytes and may require stronger signals to revert
back to less committed cell types such as DE progenitors. Hence, USSC may have a more restricted
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Figure 9 Activin receptor (ACVR) protein levels. Representative light micrographs (400×) depicting the localization of ACVR (brown staining)
in USSC grown in SCPM. Nuclei are counterstained blue with Haematoxylin. USSC 1 (left column) and USSC 2 (right column) expressed ACVR1b
(A, B), ACVR2a (C, D) and ACVR2b (E, F). No staining was detected in the IgG controls (G, H).
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pluripotent capacity than initially thought and may
require partial reprogramming to form endodermal
progenitors.

Conclusions
In conclusion, although cord blood-derived USSC have
the potential to form cells derived from the endoderm,
this study demonstrates that they do not form Sox17+
DE when treated with Activin A or IDE1/2; conditions
that specify hESC endoderm differentiation. This indicates that USSC respond differently to hESC when
induced with Activin A and that there is a fundamental
difference in the multipotent capacity of these two types
of stem cells. Clearly, further characterization of USSC
is required in order to fully understand and realize the
potential of USSC, and allow us to understand their
position in the hierarchy of lineage of human stem cells.
Additional material
Additional file 1: Activin A induction strategy. Cells were divided into
one of three treatment groups; Normal serum control, Low serum control
and Activin A. Normal serum control cells were seeded in SCPM
containing 30% FCS and then cultured in SCPM containing 30% FCS for
three days. For all treatment groups, the media was changed daily. Low
serum control and Activin A cells were seeded in serum-free SCPM. Media
was replaced with the following; serum-free SCPM on Day 1, SCPM
containing 0.2% FCS on Day 2 and SCPM containing 2% FCS on Day 3;
the media for Activin A cells on Days 1 to 3 was supplemented with
100 ng/ml Activin A.
Additional file 2: Cell proliferation index. The number of cells counted
when USSC grown in SCPM containing 0%, 1%, 2% or 30% FCS for seven
days are expressed as a percentage of the number of cells seeded. <100%
initial seeding density indicates cell death has occurred, while >100%
initial seeding density indicates cell proliferation has occurred. Different
letters denote statistical significance (P < 0.05).
Additional file 3: Activin receptor (ACVR) protein levels in USSC
grown in serum free conditions. Representative light micrographs
depicting the localization of ACVR (brown staining) in USSC grown in
serum free conditions (SCPM containing 0% FCS; 400×). Nuclei are
counterstained blue with Haematoxylin. USSC 1 (left column) and USSC 2
(right column) expressed ACVR1b (A, B), ACVR2a (C, D) and ACVR2b (E, F).
No staining was detected in the IgG controls (G, H).
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